Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.
Tobias J, Drinić M, Högler S, Ambroz K, Baier K, Kodajova P, Tomasich E, Berghoff AS, Schmid A, Garner-Spitzer E, Kenner L, Kundi M, Zielinski CC, Wiedermann U. Tobias J, et al. Transl Oncol. 2022 May;19:101378. doi: 10.1016/j.tranon.2022.101378. Epub 2022 Mar 5. Transl Oncol. 2022. PMID: 35259675 Free PMC article.
Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees.
Garner-Spitzer E, Kundi M, Rendi-Wagner P, Winkler B, Wiedermann G, Holzmann H, Herzog C, Kollaritsch H, Wiedermann U. Garner-Spitzer E, et al. Vaccine. 2009 Jan 7;27(2):197-204. doi: 10.1016/j.vaccine.2008.10.045. Epub 2008 Nov 7. Vaccine. 2009. PMID: 18996424 Clinical Trial.
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, Bartsch R, Steger G, Pehamberger H, Scheiner O, Zielinski CC. Wiedermann U, et al. Breast Cancer Res Treat. 2010 Feb;119(3):673-83. doi: 10.1007/s10549-009-0666-9. Breast Cancer Res Treat. 2010. PMID: 20092022 Clinical Trial.
Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10.
Garner-Spitzer E, Wagner A, Paulke-Korinek M, Kollaritsch H, Heinz FX, Redlberger-Fritz M, Stiasny K, Fischer GF, Kundi M, Wiedermann U. Garner-Spitzer E, et al. J Immunol. 2013 Sep 1;191(5):2426-36. doi: 10.4049/jimmunol.1300293. Epub 2013 Jul 19. J Immunol. 2013. PMID: 23872054
Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias.
Garner-Spitzer E, Seidl-Friedrich C, Zwazl I, Hofer M, Kinaciyan T, Jarisch R, Stiasny K, Zlabinger GJ, Kundi M, Wiedermann U. Garner-Spitzer E, et al. Vaccine. 2018 May 11;36(20):2816-2824. doi: 10.1016/j.vaccine.2018.03.076. Epub 2018 Apr 16. Vaccine. 2018. PMID: 29673942 Clinical Trial.
Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept.
Guzek A, Berghoff AS, Jasinska J, Garner-Spitzer E, Wagner A, Stiasny K, Holzmann H, Kundi M, Zielinski C, Wiedermann U. Guzek A, et al. Ann Oncol. 2020 Feb;31(2):319-321. doi: 10.1016/j.annonc.2019.11.005. Epub 2019 Dec 20. Ann Oncol. 2020. PMID: 31959351 Free article. No abstract available.
27 results